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Individual biological differences may contribute to the variability of outcomes, including cognitive effects, observed following
electroconvulsive treatment (ECT). A narrative review of the research literature on carriage of the apolipoprotein E ε4 allele (APOE-
ε4) and the protein biomarker beta amyloid (Aβ) with ECT cognitive outcome was undertaken. ECT induces repeated brain seizures
and there is debate as to whether this causes brain injury and long-term cognitive disruption. The majority of ECT is administered to
the elderly (over age 65 years) with drug-resistant depression. Depression in the elderly may be a symptom of the prodromal stage
of Alzheimer’s disease (AD). Carriage of the APOE-ε4 allele and raised cerebral Aβ are consistently implicated in AD, but
inconsistently implicated in brain injury (and related syndromes) recovery rates. A paucity of brain-related recovery, genetic and
biomarker research in ECT responses in the elderly was found: three studies have examined the effect of APOE-ε4 allele carriage on
cognition in the depressed elderly receiving ECT, and two have examined Aβ changes after ECT, with contradictory findings.
Cognitive changes in all studies of ECT effects were measured by a variety of psychological tests, making comparisons of such
changes between studies problematic. Further, psychological test data-validity measures were not routinely administered, counter
to current testing recommendations. The methodological issues of the currently available literature as well as the need for well-
designed, hypothesis driven, longitudinal studies are discussed.
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OVERVIEW
Electroconvulsive treatment (ECT) of mental illness is a ‘Blind Tool’:
when, how, why and if it works, is unpredictable. The diseases,
disorders, syndromes and conditions treated by electrical-induced
convulsions have few commonalities, or measured aetiologies; the
mechanisms of its actions upon the brain are known imprecisely,
and its causal relationship to outcome is unknown. Yet, ECT is
demonstrably effective in the relief of some of the major
psychopathologies.
This review focuses on genetic, protein biomarker and
neuropsychological research associated with the variable ECT
recovery patterns observed in the literature. Specifically, the
potential utility of conceptualising ECT as controlled, transient
minimal brain change is considered. In addition, evidence for the
relationship between the variable ECT recovery patterns and
individual biological differences as determined by carriage of the
apolipoprotein E ε4 (APOE-ε4) allele and by levels of the protein
biomarker beta amyloid (Aβ) will be discussed. This review aims to
identify the next steps for future research and potential additions/
modifications to protocols for ECT use in clinical environments, as
well as possible complications and health benefits in patients over
the age of 65 years treated with ECT.
BRIEF BIOGRAPHY OF ECT
Convulsions caused by electrical stimulation were first used in
1938 on an individual with schizophrenia suffering delusions and
hallucinations, by Cerletti and Bini.1 The patient was reported as
having received a beneficial seizure, which restored him to ‘clear-
headedness’ and health. According to Aruta,2 however, in contrast
with the published account of the patient simply having a
‘successful’ seizure, he had three failed prior attempts at inducing
a seizure, each with increasing voltages. Further, it is reported that
the patient “shouted at Cerletti not to administer the ‘deadly’
shake…”, and while Cerletti and Bini described the patient as
making a full recovery, he actually relapsed 2 years later. Hence,
variable recovery following ECT has been noted from the start.
In the 1930s, Meduna, and others, classified what we now term
mood disorders with the depressive and anxious expressions of
those with the alternating stupor and excitement of catatonic
schizophrenia.3 Gradually, ECT was seen to especially benefit
depression,1,4 although depression may or may not have been a
discrete disorder. Lothar Kalinowsky (1899–1992), a German
psychiatrist, during the same early period, urged that ECT should
not be used on those with character disorders and anxiety, again
defined by the theories of the moment.
ECT is usually now used only when other treatments have been
ineffective, poorly tolerated or there is a need for rapid change,
such as acute and intense suicidal behaviour. ECT is recom-
mended for use by the American Psychiatric Association Task
Force on ECT,5 Royal College of Psychiatrists Special Committee on
ECT6 and the Institute for Health and Clinical Excellence7 for the
following diverse conditions:
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● Severe depression (unipolar and bipolar)
● Acute mania (and bipolar mixed states)
● Schizophrenia
● Catatonia
Further, ECT has been approved by the US’ Food and Drug
Administration for use in depression, unipolar and bipolar
disorders, schizophrenia, bipolar manic and mixed states, schiz-
oaffective disorder, schizophreniform disorder and catatonia.8
The original ECT ‘…devices used 125 volts, 50 hertz line
current…modified only by a simple mechanical timing mechan-
ism based on a metronome’.9 The current procedures used for the
administration of ECT have not changed in principle since
Holmberg and Thesleff published their protocol in 1952 advocat-
ing the use of succinyl-choline-iodide to produce muscular relaxa-
tion and reduce the convulsions without the risk of prolonged
respiratory difficulties.10 (Of note, succinylcholine mimics the
choline end of acetylcholine, making it an acetylcholinesterase
inhibitor.11 The latter is targeted by donepezil, rivastigmine and
galantamine, drugs commonly used in the treatment of early
stages of Alzheimer’s disease (AD). The hypothesis is that lower
concentrations of acetylcholine are found in those with AD; hence,
keeping levels up might be useful. If a depressed ECT patient is in
prodromal AD, the use of any acetylcholinesterase inhibitor
becomes a confounding factor in teasing out the efficacy of
variables.) The intervening years have seen three changes in the
technique: the use of anaesthesia and muscle relaxants, brief and
ultra-brief pulse stimuli and unilateral non-dominant hemisphere
electrode placement options. These replaced the bite guard, raw
current and bilateral placements. Entry and exit points of electric
current are either bi-frontal or unilateral, usually on the right side.
In any event, regardless of electrode placement, wave shape and
pulse interval, a generalised seizure is generated producing
widespread bursts of abnormal excitatory synaptic activity in the
central nervous system.
ECT, BRAIN INJURY AND COGNITIVE CHANGE
There is debate surrounding the issue of whether the transitory
neural changes caused by ECT-induced seizures produce long-
term structural or neurochemical alterations contributing to
cognitive impairment. The studies reviewed below highlight
variable results with respect to both the questions of whether
ECT causes any form of brain injury; and whether ECT causes any
form of permanent cognitive change. The last issue has two parts:
whether cognitive changes, if they occur, are positive or negative.
For example, Kroes et al.12 showed that one dose of ECT prevents
the adequate consolidation of reactivated negatively charged
episodic memory after a time delay of 1 day (raising the possibility
of modifying negatively emotionally charged episodic memories),
whereas a raft of other studies show gross autobiographical
memory loss as an undesired outcome.13 Methodological varia-
tions, which will be discussed in detail later, may contribute to the
varying results reported.14
SEIZURE-INDUCED BRAIN INJURY
Sommer, collecting others’ autopsy reports and his own observa-
tions, found that in 90 cases between 1825 and 1880, of
individuals with a history of seizures due to epilepsy, 30% had
pathological changes in the hippocampus.15 Sommer’s sector
refers to a region of Ammon’s horn within the hippocampus
where he described in detail severe neuronal loss. The hippo-
campus is associated with memory formation and its dysfunction
is evident in early AD.
Inherent features of the hippocampal neuron are proposed to
account for seizure-induced cell death.15 The neurons of Sommer’s
sector (CA1) and CA3/4 have more receptors for the excitatory
neurotransmitter glutamate than neurons in the more resistant
sectors of the hippocampus.16 An overabundance of glutamate
released at synaptic terminals during disease states such as
epilepsy can be toxic due to a sudden and detrimental
postsynaptic Ca++ influx, and neurons especially prone to cell
death are richer in glutamate receptors (causing the so-called
glutamate excitotoxicity). Aggravating the tendency for neurons
to succumb to excitotoxicity, the more vulnerable neurons of CA1
and CA3/4 have less Ca++ buffering capability, due to small
concentrations or absence of calbindin and chromogranin A
compared with the more resistant neurons of CA2 and granule
cells of the dentate gyrus.17 Therefore, a poor ability to protect
against the excitotoxic effects of glutamate subsequently leading
to cell death, by Ca++ influx, is the pathogenic mechanism of
Ammon’s horn sclerosis.15
Seizures induce many changes in gene expression in the
nervous system, which can lead to the development of chronic
epilepsy and/or neurodegeneration.18 It is generally acknowl-
edged that convulsive status epilepticus leads to brain injury.19–22
Further, there is growing evidence that non-convulsive status
epilepticus can also lead to brain injury.23,24
Work on animal models indicates that brief single seizures can
lead to apoptotic neuronal death bilaterally in the rat dentate
gyrus.19 Complex and simple partial seizures without convulsions
cause increased risk for new or increased neurological deficit.23
Further, it has been shown that, even without attendant
hypoxaemia, acidosis, hyperthermia and hypoglycaemia, ongoing
seizures in primates and rats can cause neuronal death.25,26
A review of human research involving neuropathological
studies, magnetic resonance imaging and magnetic resonance
spectroscopy of epileptic patients experiencing repeated brief
seizures indicates brain injury occurs more often than not.20
Hippocampal sclerosis is evident in two-thirds or more of
hippocampal specimens from temporal lobe epilepsy (TLE)
patients (n= 572), those with extra-temporal seizures and
pathologies (n= 73) as well as among anterior temporal lobec-
tomy and hippocampectomy specimens from patients with
medically intractable TLE (n= 183).27,28 Hippocampal volume loss
is reported after seizures,29 whereas TLE, the most common of the
transient seizure syndromes, results in widespread atrophy
including the hippocampus, occipitotemporal areas, cerebellum,
cingulate cortex, the ipsilateral insula and thalamus.30 Sutula
et al.20 summarises their review of the literature by stating that
‘The emerging perspective is that seizure-induced damage should
be regarded not only as neuronal loss but as adverse long-term
behavioural and cognitive consequences’. Whether such pathol-
ogy manifests following ECT-induced seizures, however, remains
to be determined.
STUDIES OF ECT AND NEURAL INJURY
ECT studies have produced apparently more optimistic findings as
to whether injury to the brain occurs following the type of
repeated seizures ECT procedures induce. A number of studies
found no neuronal injury following bilateral ECT,31,32 whereas
others report that ECT can have a ‘positive effect on restoring grey
matter volume’ in treatment-resistive depression.33 Restoration to
normal levels of cortical glutamate/glutamine34 has been
described, whereas others conclude that there ‘is no credible
evidence that ECT causes structural brain damage’.35,36 Interest-
ingly, a case report detailing post-mortem brain examination of an
84-year-old man who had undergone 422 ECT sessions described
no significant microscopic abnormalities, once again suggesting
that ECT is not associated with identifiable structural brain injury.37
Despite this apparent consensus regarding a lack of association
between ECT and neural injury, methodological variations exist
between the studies described above suggesting that caution is
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required when interpreting such findings; these variations will be
discussed in a later section.
COGNITIVE CHANGE
In contrast to the general agreement between reports of ECT and
absence of neural injury, studies of cognition have produced
conflicting results as to the presence or absence of prolonged
cognitive change following ECT. It has been reported that
individuals referred for ECT due to drug-resistant depression,
when matched and compared with those with depression but not
referred for ECT, produced different cognitive profiles.38 The
former were weaker on executive tasks, the latter on memory,
suggesting subtypes of depressives with dissimilar baseline
cognitive profiles to begin with. Numbers were small (n= 15 in
each group) and all were female. An exceptionally detailed
neuropsychological evaluation of the long-term outcome of ECT
and cognitive change in those with bipolar disorder found
significant verbal memory impairments at 6 months post bilateral
ECT.39
In a review of 84 studies, Semkovska and McLoughlin40
concluded that cognitive disruption occurs over 3 days post ECT
and subsequently resolves, and that after 15 days there is
improvement in speed of processing information, working
memory, anterograde memory and some executive functions
above baseline.
A seminal study found electrode placement position to be
important in causing more or less cognitive disruption at 6 months
follow-up, with bilateral placement the more disruptive.13 Older
age was correlated with poorer outcome, and greater cognitive
reserve with better outcome. Lack of control groups prevented
any conclusions about post-ECT cognitive recovery returning to
premorbid levels. This study is rare in its use of reaction time as a
measure of speed of processing. The authors also found longer
waveforms to be more deleterious in terms of cognitive
disruption.13
Following on from the earlier work of Sackheim et al.,13 Verwijk
et al.41 conducted a review of 10 studies focusing on cognitive
outcomes following brief and ultra-brief pulse ECT. The authors
concluded that autobiographical memory and word fluency (word
finding) were impaired immediately post ECT, and to a lesser
extent up to 6 months post ECT. Conversely, verbal memory, visual
scanning and symbol-coding performance returned to baseline or
improved. The authors noted, however, that there were too few
studies to draw conclusions about cognitive functions other than
memory. Overall, Verwijk et al.41 could not fully conclude that
cognitive functions returned to premorbid levels at 6 months post
ECT treatment.
Loo et al. concluded that although ultra-brief ECT likely causes
less cognitive impairment than other pulse width regimes, some
cognitive impairment may still occur. The authors also noted that
treatment efficacy is not yet demonstrated and therefore this
approach should only be used in research designs.42 Sienaert
et al.,43 by contrast, using an extensive range of neuropsycholog-
ical tests, concluded that no dysfunction occurs following ultra-
brief ECT. Unfortunately, however, the same tests were given on
three occasions with no allowance for practice effects or use of a
reliable change index correction.
The major complaint of some patients following ECT is the loss
of autobiographical memory. This is a failure of the episodic
memory system44 as distinct from semantic memory. The former
refers to recalling an event in the past that one is aware to have
occurred in the past to oneself. Retrieval from the semantic system
is the recall of factual material, and does not require awareness of
one’s own experience of that fact in the past. For example,
recalling what was eaten for breakfast yesterday is episodic,
remembering the pulse time distinction between brief and ultra-
brief ECT is semantic. The dissociation between episodic and
semantic systems is seen in case studies of patients with traumatic
brain injury.45
Fraser et al.46 reviewed 15 studies of ECT and autobiographical
memory and came to mixed conclusions due to the difficulty in
establishing the construct validity of the various subjective
autobiographical memory measures used in the studies. The
authors suggest that levels of autobiographical memory loss
correlate with the type of treatment procedure: bilateral and sine
wave ECT administration had a more deleterious effect than
unilateral and brief pulse procedures. As noted above, Verwijk
et al.41 did find that autobiographical memory was impaired
immediately post ECT, and to a lesser extent, but still present, up
to 6 months post ECT.
Memory loss following ECT might be desirable. Treatment of
psychological disorders often involves manipulating episodic
memories (cognitions, thoughts and beliefs) to some degree
and in some fashion. Theoretically, loss of distressing memories
will cause loss of the associated negative effect. Kroes et al., while
investigating the recall process of negatively charged episodic
memory, found the consolidation of an earlier learned distressing
event (stories and visuals) was disrupted following a single session
of ECT if the memory was ‘reactivated’ just prior to ECT and
measured 1 day post ECT.47 Causation of the disruption to
memory consolidation in this study could not be factored out, as
either the seizure and/or anaesthetic could be involved.
A more recent retrospective case-note study (n= 126), however,
indicated that patients benefited from ECT on global cognition (as
measured by the Mini Mental State Examination) but experienced
transient cognitive decline within the first 3 months, as indicated
in the spatial recognition memory subtest of the Cambridge
Neuropsychological Test Automated Battery.48 Possible explana-
tions of the conflicting results reported regarding the presence or
absence of prolonged cognitive change following ECT will be
discussed in detail in a subsequent section.
DEPRESSION, THE ELDERLY AND DEMENTIA
Depression, mild cognitive impairment (MCI) and AD are linked,
with MCI seen as a potential prodromal stage of AD.49 MCI is a
syndrome where cognitive decline is greater than expected for
the person's age and educational level but activities of daily living
are not significantly impacted.50 Statistically, a portion of the
elderly with depression receiving ECT may develop either MCI or
AD. Depression occurs in 8–16% of the older community.51,52 The
elderly, defined as either over 60 or 65 years of age, comprise a
significant group receiving ECT, and are over-represented
compared with younger age groups.14,53
Depression as a risk factor for AD was seen in a retrospective
study.54 Despite the study being based on the recall of subjects,
more diagnoses of depression were found in those who
developed dementia than in controls, on average some 6 years
prior. This is a consistent finding in all subsequent research. Diniz
et al.,55 in a systematic review and meta-analysis of 23 studies
found late-life depression was associated with an increased risk for
various dementia syndromes including vascular dementia and AD.
Hausner et al.56 found ECT to be safe for older (65–89 years)
depressed patients, regardless of a diagnosis of dementia, MCI or
no cognitive impairment. Hausner et al. concluded that ECT does
not induce cognitive deficits, regardless of baseline cognitive
status. The latter was measured by the Mini Mental State
Examination, a global screening measure of cognitive status with
low ceiling effects and relatively poor sensitivity to subtle
cognitive changes, 6 months post ECT. The test was repeated
three times at the sixth-treatment, 6-week and 6-month marks,
making no allowance for practice effects. Samples were small for
the cognitively impaired groups: MCI (n= 19) and dementia
(n= 12) with the range of scores at 6 months post ECT between
20–30 for the MCI group, and 22–29 for the dementia sample. This
ECT, APOE and recovery of cognitive functions
TA Sutton et al
3
Translational Psychiatry (2015), 1 – 8
indicates wide variability in functioning among cognitively
impaired groups, and some individuals with dementia were not
scoring as such on the test.
Other studies of ECT in the elderly also suffer from design
limitations. For example, while attempting to compare bilateral
with unilateral electrode placement, one study was able to
reassess only 35% of the subject group due to refusal or lack of
consent capacity, ensuring that cognitive changes in the majority
of the sample could not be evaluated.57 A Cochrane review aimed
at assessing the efficacy and safety of ECT in depressed elderly
could find only four randomised studies meeting their criteria, all
of which had serious methodological problems, preventing any
conclusion being drawn. It was therefore not possible for the
authors to determine whether ECT is more effective than
antidepressants, nor could any conclusion be made as to the
safety or side effects of ECT in the depressed elderly.58
Moreover, depression is conceptualised and measured in each
study quite differently. Simple screening measures or symptom
checklists specific to depression are routinely utilised. In MCI,
depressive symptoms may also be those of cognitive change; for
example, sleep disturbance, poor concentration and anhedonia:59
these factors make it difficult to conceptually disentangle a
depressive from a cognitive symptom. Uniform utilisation of more
comprehensive assessments may facilitate differential diagnosis,
and further work in the area of ECT, depression, the elderly and
dementia is required.
ECT AND APOE-Ε4
Apolipoproteins such as ApoE bind to low-density lipoprotein
receptors thereby mediating transport of cholesterol and other
lipoproteins. This transported cholesterol is used to make
dehydroepiandrosterone, sex hormones and the glucocorticoster-
oids. The latter, at elevated levels, mimics the effects seen in post-
traumatic stress disorder in the hippocampus, and negatively
affects memory.60,61 ApoE is encoded by the APOE gene, located
on chromosome 19, which has three major alleles: ε2, ε3 and ε4,
related to amino-acid substitutions (Arg and Cys) at positions 112
and 158 of the protein. These single amino-acid substitutions
result in significant functional differences. The frequency of APOE
alleles in the Australian population is similar to other western
countries: APOE-ε2 8%, APOE-ε3 78% and APOE-ε4 14%.62
Possession of the APOE-ε4 allele has become firmly established
as a risk factor for the incidence of late-onset AD (LOAD).63 The
frequency of the ε4 allele in familial LOAD was found to be 50%
compared with 14–16% for controls64 and 40% in those with
autopsy-confirmed AD pathology but no family history.65 AD risk
and APOE-ε4 carriage is dose dependent: individuals who are
heterozygous and homozygous for APOE-ε4, have a threefold and
eightfold increased risk of developing LOAD by age 80 years,
respectively. Importantly, however, 50% of those who are
homozygotic for APOE-ε4 survive up to the age 80 years without
cognitive impairment, such that the possession of this genetic
configuration is not deterministic. Levels of cerebral Aβ deposi-
tion, a hallmark of AD, are directly related to inheritance of an ε4
allele, although the increased Aβ deposition observed in ε4/ε4 and
ε3/ε4 patients is not related to survival times.63
The APOE gene while primarily expressed in hepatic parenchy-
mal cells,66 is also expressed in the brain, where the ApoE protein
is produced mainly by astrocytes. Astrocytes synthesise ApoE,
which combines with cholesterol and phospholipids to form lipid–
protein complexes, that are postulated to maintain and repair
nerve cell membranes, aid neuritic growth and facilitate synapto-
genesis. The repair process occurs when the lipid–protein complex
is released into the extracellular space and taken up by ApoE
receptors on the nerve cell surface, before being internalised into
the cell. It is thought that ApoE itself transports lipids within the
brain, enhances the structural integrity of microtubules within the
neuron and possibly facilitates neural transmission.
It has been reported that individuals carrying the APOE-ε4 allele
are prone to experiencing a slower recovery from brain injury.67 If
ECT causes neural injury, then recovery from experiencing ECT
should also be prolonged in those who carry the APOE-ε4 allele.
Only three studies have examined ECT response and carriage of
the APOE-ε4 allele. Interestingly, Fisman68 found that those with
APOE-ε4 and late-onset depression, but not psychosis, had a better
response to ECT than ε4 non-carriers, whereas Huuhka et al.69
found no differences in response to ECT, regardless of APOE
genotype. In agreement with the results of Huuhka et al., Bousman
et al.70 also reported no association between APOE genotype,
treatment efficacy and cognitive side effects of ECT among 117
participants with major depressive disorders undertaking ECT
through clinical study participation. Bousman et al.70 concluded
that the younger age of their cohort may account for the
disparate results, with APOE contingent effects apparent only in
older age. Further work is required, however, to validate these
findings.
Fisman et al.68 point out that the good response to ECT in those
with APOE-ε4 is ‘counter-intuitive’, given the previously cited links
between APOE-ε4 Aβ deposition after brain injury,71 and its
association with AD. To account for the observed response,
Fisman et al. hypothesise that the APOE-ε4 genotype regenerates
proximal dendrites, producing a greater antidepressant effect. The
authors base their hypothesis partly upon the work of Arendt,72
and partly on the discussions and hypotheses of Duman and
Vaidya.73 The former, in the view of Fisman et al., showed that
those with ε3/3 alleles regenerated more distal dendritic
segments, whereas ε3/4 carriers regenerated both distal and
proximal dendritic parts, and ε4/4 carriers localised regrowth
closer to the soma.72 Duman and Vaidya73 discuss research on ECT
causing an increase in the brain-derived neurotrophic factor,
which they hypothesise then reverses the atrophy of stress-
vulnerable neurons or protects these neurons from further injury.
Arendt72 worked on autopsied brain specimens and observed
impairment of neuronal repair in those possessing the APOE-ε4
allele, whereas Duman and Vaidya73 reviewed diverse findings
from animal and human research. Notably, despite the hypothesis
by Fisman et al. being speculative, and the drawbacks in their
research design, this single study is cited in 10 articles as
confirmatory of the link between APOE-ε4 and a successful
response to ECT.
The study by Huuhka et al.69 is methodologically firmer than
that of Fisman et al.68 All patients received the same ECT
procedure (bilateral) and the outcome criteria was defined by
clearly separating good and poor responders with non-lapping
scores on the Montgomery–Asberg depression rating scale: o8
for responders and 415 for non-responders. As with Fisman et al.,
there were mixed diagnostic groups: patients with depression
with or without psychosis. The patient age range was 22–84 years.
Early onset of depression was defined as o45 years and late
onset as 445 years of age, and psychotropic medication was
present.
In summary, the only three studies in this area are conflictual
and suffer multiple methodological limitations. They reflect the
difficulty in undertaking ECT research while simultaneously
attempting to treat patients within the clinical context.
ECT AND Aβ
Histopathologically, LOAD is characterised by senile plaques and
neurofibrillary tangles. The latter are aggregates of the hyperphos-
phorylated tau protein. The plaques are mainly composed of
aggregated Aβ peptides derived from the amyloid precursor
protein encoded on chromosome 21. AD is therefore, likely to be
at least in part, a function of beta-protein amyloidosis. Aβ is
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suggested by some to be important in maintaining synaptic
function, learning and memory,74 with its causal role in AD
overemphasised.
Aβ, first described in 1984,75 results from proteolytic cleavage of
the amyloid precursor protein, of which two short amino-acid
sequences, Aβ1–40 and Aβ1–42 are products.
74 Aβ1–42 is more
amyloidogenic than Aβ1–40.
76 Although Aβ1–42 amino-acid pro-
duction is, overall, less common than the 1-40 type, it is the
dominant kind of Aβ found in the amyloid plaques of those
with AD.
Only two studies of Aβ levels following ECT could be found.
Zimmerman et al.77 measured plasma Aβ peptides 1-40 and 1-42
before ECT, ~ 30 min post ECT and at ~ 2 and 24 h after ECT
treatment in 13 patients. The average age of the sample was 50.86
(s.d. 14.5 years). The diagnoses included depressive episodes in
bipolar affective disorder or in recurrent depressive disorder with
or without psychotic symptoms (seven patients), and depressive
type of schizoaffective disorder. The brief-pulse stimulation
technique was applied with right unilateral stimulation in each
patient.
The authors found a significant increase in the plasma
concentrations of each Aβ species ~ 30min after ECT, followed
by normalisation of the peptide’s concentrations 2 h after ECT.
Specifically, elevations in Aβ following ECT at 30min were
between 5 and 10% from baseline, normalised at 2 h and
remained normal at 24 h. Aβ levels were not correlated with the
number of ECT sessions or the electroencephalogram-measured
seizure duration.
Further, in a first study to analyse Aβ before and after ECT in 25
drug-resistant bipolar depressed patients, Aβ1–40 and Aβ1–42, as
well as their relative ratio were measured before and after
3–4 weeks of ECT.78 Although the authors were not able to
identify changes in plasma concentrations of these isoforms post
treatment, they did observe a positive correlation between Aβ1–40/
Aβ1–42 ratio and severity of depressive and cognitive symptoms, as
determined by Clinical Global Impressions-Severity of Illness Scale
score and the Hamilton Rating Scale for Depression (HRSD-21)
score; that is, the higher the biological parameters, the more
severe the condition. Furthermore, individuals who entered
clinical remission after ECT presented a significantly lower Aβ1–40/
Aβ1–42 ratio at baseline, compared with non-remitters, suggesting
a possible method of characterising depressed individuals who
may respond positively to ECT.
One difficulty in interpreting these results is that, whereas
plasma and cerebrospinal fluid (CSF) measures of Aβ1–40 and
Aβ1–42 might correlate in healthy subjects, they might not in those
with AD, where CSF levels are the more discriminatory.79–81 To
date, no study has reported Aβ levels in the CSF following ECT.
Such a study could have significant scientific impact on our
understanding of the potentially damaging or beneficial effects
of ECT in relation to a molecule heavily implicated in AD
neurodegeneration.
If the depressed elderly benefit from ECT, and a proportion
have prodromal AD, and if cognition improves, then a causal
mechanism between seizure activity and cognitive improvement
should exist. If AD is correlated with increased Aβ, then one
hypothesis is that this protein is affected by ECT: there should
be less Aβ in the brains of successfully ECT-treated older
dementia patients. Positron emission tomography imaging utilis-
ing Aβ-binding radiolabelled tracers (for example, carbon-11-
labelled Pittsburgh Compound-B; C11-PiB) yielding estimates
of cerebral Aβ load would be required to test this hypothesis.
This relationship has not been previously examined and
should, where possible, be included in future studies of ECT
and Aβ. Further, amyloid imaging can serve as an outcome
measure if proved to be significantly associated with ECT
application.
METHODOLOGICAL VARIATIONS AS POTENTIAL
CONFOUNDERS
Despite the apparent consensus regarding a lack of association
between ECT and neural injury, methodological variations
between studies quell the robustness of such a conclusion. The
studies showing no brain injury results from ECT, suffer problems
of patient heterogeneity with variable diagnoses, large age ranges
(20–80 years), gender and educational differences. Further
limitations are imposed by small sample sizes; variable numbers
of ECT sessions; bilateral, unilateral, brief and ultra-brief ECT
procedures; and various biological markers assessed after variable
times (from the initial treatment session to some days following).
Inter-study methodological variations may also provide a
possible explanation for the conflicting results reported regarding
the presence or absence of prolonged cognitive change following
ECT. Few studies have control groups of any sort, and even fewer
control for confounding variables such as the type of anaesthetic
used. In addition, cognitive reserve or premorbid estimates of
functioning were measured in only two studies;13,82 the depressed
elderly are often combined with younger age groups in the data
analysis. Further, the elderly are prone to depression83 that in turn
can be a prodromal stage risk factor for AD, which is itself
evidenced by severe cognitive dysfunction.84,85
Cognitive change covers many functions, including various
types of memory, speed of information processing, language
processing, executive functions and reasoning. Neuropsychologi-
cal testing requires a validity measure or measures, assessing
whether optimal cognitive performance and hence valid data,
have been obtained.86 Historically, the term ‘symptom validity
test’ or ‘response bias’ and later the 'performance validity test'87,88
was used to describe such measures. However, no such measure
was obtained as part of the studies described.
In their review of 84 studies assessing ECT and cognition,
Semkovska and McLoughlin40 note the problem of researchers
collapsing visual and verbal memory data into one, and failing to
discriminate between the various memory processes such as
encoding, retrieval or learning. The authors identified 22 different
neuropsychological tests across the studies reviewed, with four
different wordlist tests, two short-story tests, two paired word
associate tests and three visual memory tests among the memory
measures, highlighting the lack of uniformity among research
cognitive measures. Semkovska and McLoughlin40 integrated
what they themselves categorised as ‘similar tests’ in their
analysis, such as treating the results from all wordlist tests as
one. This approach, however, limits interpretation of results: for
example, the Rey Auditory Verbal Learning Test contains discrete
and unrelated words, whereas the California Verbal Learning Test
has words that can be categorically grouped, changing the
potential encoding strategy required. In addition, the authors
report that no pre-treatment data were available in any study,
although in fact one included a formal estimate of premorbid
intellectual functioning for baseline purposes, the National Adult
Reading test.82 Further, the age ranges in the 84 studies was
between 18 and 87 years, contained differing and multiple
diagnostic groups of unknown severity, employed different ECT
electrode placements and procedures and tested subjects at
differing time intervals (between 45min and 12 months) during
and post ECT administration.
The review by Verwijk et al. of ten studies focusing on cognitive
outcomes following brief and ultra-brief pulse ECT41 also
incorporated studies using a multiplicity of neuropsychological
measures across a range of functional areas (rote visual and verbal
memory, visual scanning speed, working memory, executive
processing and visuospatial organisation), as well as different
inclusion and exclusion criteria for subjects, age ranges between
14 and 91 years, small samples sizes and different points at which
post-ECT functions were measured. However, the authors did note
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that study number and heterogeneity prohibited robust conclu-
sions to be drawn.
The studies of APOE, Aβ and ECT also suffer from methodolog-
ical variations, which limit the interpretability of their findings. For
example, the study of APOE and ECT by Fisman is marred by a lack
of diagnostic patient selection, there being a mix of depression
and schizoaffective disorder; differing ECT procedures (unilateral
and bilateral) per subject; inter-rater response outcome criteria
disagreement in 17.6% of cases; and patients simultaneously
being on additional medications affecting brain chemistry. Among
Fisman’s sample, no successful responder to ECT with APOE-ε4
had psychotic features or early-onset depression. Furthermore,
the age range of those with APOE-ε4 when first diagnosed
with depression was 54–72 years, and those without the allele,
15–81 years; early and late onset was defined by the median age
in these ranges.68
Methodological issues, although detrimental, can be properly
addressed through detailed, well-designed studies, something
long needed in ECT research. Although such methodological
variations are not exclusively seen in ECT research, they should be
considered when any conclusion is drawn based on the currently
available literature.
DISCUSSION AND CONCLUSIONS
Clinical necessity compels the continued use of ECT, and its use
has been increasingly seen in the elderly worldwide. However,
ECT’s effect on cognitive functions, particularly among older
adults, remains decidedly unclear due to the methodological
issues in the published research.
First, there is heterogeneity of patients’ characteristics, including
a multiplicity of diagnoses and variability in their definitions,
extreme age ranges, gender ratios, the presence of prodromal or
existing neurodegenerative diseases such as AD, variable cogni-
tive reserve capacities among subjects and biological variability
such as differences in known genetic risk factors for AD (for
example, APOE-ε4) and/or recovery from acquired brain injury.
Second, there is heterogeneity of emotional measures, each
usually restricted to one global construct such as ‘depression’. The
psychological measures are usually brief screeners, with few items.
Third, there is heterogeneity of cognitive measures. These range
from brief, often insensitive global estimates of cognitive
functions such as the Mini Mental State Examination, to a variety
of word list, story and associative verbal memory tests, a variety of
measures of visual memory and visuospatial skills, speed of
processing information and executive functions. Only one study
utilised reaction-time tasks and one included an estimate of
premorbid level of functioning (or possible cognitive reserve). It is
rare for practice effects to be addressed; for example, by using
parallel forms of tests or utilizing reliable change indexes based
upon the psychometric properties of the instrument (error
ranges). There is also complete absence of performance validity
test measures, which are required to ensure cognitive data
are valid.
Finally, there has been heterogeneity of experimental proce-
dures: cognitive and biomarker valuations are conducted at
different times during and post ECT, ranging from minutes to
months. Control groups, including sham ECT or epileptic subjects,
are poorly selected or absent.
The practical difficulty of ECT research stems from the
conundrum posed by clinical urgency. ECT is only used, and is
only acceptably used, in intractable and severe cases of mental
suffering. Research to date has typically targeted experimental
control over clinical application—for example, dropping atypical
cases to ensure ‘outliers’ are not contaminating any effect. Case
studies where an experimental n= 1, are more practical and may
yield additional useful information. This approach is also better
suited to research a highly specific question (for example, is CSF
Aβ level changed following ECT?) with a specific patient (specified
age and a measured diagnosis with construct validity) utilising
relevant cognitive outcome measures (using theoretical terms
compatible with the psychometric measures).
Standardisation of measures of cognitive functions and
biomarkers relevant to known changes in an older person (over
65 years), within a comprehensive, single-case repeated measures
design, would yield a sound basis for evaluating the cognitive
changes, positive, negative or none, between studies and research
groups. This would also allow the incorporation of data from
individual clinicians.
An agreed standardised evaluation protocol of older patients
subjected to ECT would be a useful precursor to investigating the
benefit or cost of induced seizure activity on cognition. Clinically,
this may then serve to better identify patients suitable or
unsuitable for the procedure.
Finally, although such methodological variability between
studies suggests that caution should be employed when
interpreting the results, the difficulties associated with conducting
such research must not be overlooked. Having said that, there is a
long-lasting need for properly designed clinical studies with well-
defined samples to elaborate on both cognitive and biological
markers potentially associated with ECT. Such a study can address
cost/benefit problems while providing information on duration,
intensity and dose-dependent effects/side effects of ECT as a
therapeutic intervention.
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